Late onset neutropenia and immunoglobulin suppression of the patients with malignant lymphoma following autologous stem cell transplantation with rituximab

Internal Medicine

Volumn 48, Issue 1, 2009, Pages 57-60

  Hirayama, Yasuo ^a,c   Kohda, Kyuhei ^a   Konuma, Yuichi ^a   Hirata, Yasuji ^b   Kuroda, Hiroyuki ^a,c   Fujimi, Yuko ^d   Shirao, Sayaka ^d   Kobune, Masayoshi ^d   Takimoto, Rishu ^d   Matsunaga, Takuya ^d   Kato, Junji ^d  

^a ASAHIKAWA RED CROSS HOSPITAL   (Japan)

^b Hakodate Red Cross Hospital   (Japan)

^c Higashi Sapporo Hospital   (Japan)

^d SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

Immunoglobulin; Neutropenia; Rituximab; Transplantation

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHOTREXATE; PREDNISOLONE; RANIMUSTINE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LARGE CELL LYMPHOMA; LYMPHOMA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; RETROSPECTIVE STUDY; SIDE EFFECT; WHOLE BODY RADIATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULINS; LYMPHOMA; MALE; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS;

EID: 61749087962     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.1368     Document Type: Article

References (11)

1. Nishio M, Endo T, Fujimoto K, et al. Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant-EBV-associated autoimmune hemolytic anemia. Eur J Haematol 75: 527-529, 2005.
2. Motl SE, Baskin C. Delayed-onset grade 4 neutropenia associated with Rituximab therapy in a patient with lymphoma: case report and literature review. Pharmacotherapy 25: 1151-1155, 2005.
3. Chaiwatanatron K, Lee N, Grigg A, et al. Delayed-onset neutropenia associated with Rituximab therapy. Br J Haematol 121: 913-918, 2003.
4. Flohr T, Hess G, Kolbe H, et al. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL. BMT 29: 769-775, 2002.
5. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma. Ann Intern Med 102: 596-602, 1985.
6. Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with Rituximab. N Engl J Med 26: 2691-2694, 2003.
7. Papadaki T, Stamatopoulos K, Anagnostopoulos A, Fassas A. Rituximab-associated immune myelopathy. Blood 102: 1557, 2003.
8. Klepfish A, Rachmilevitch E, Schattner A. Parvovirus B19 reactivation presenting as neutropenia after rituximab treatment. Eur J Intern Med 17: 505-507, 2006.
9. Dunleavy K, Hakin F, Kim HK, et al. B-cell recovery following rituximab-based therapy is associated with pertubations in stromal derived factor-1 and granulocyte homeostasis. Blood 106: 795-802, 2005.
10. Lemieux B, Tartas S, Traulle C, et al. Rituximab-related late onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 33: 921, 2004.
11. Cairoli R, Grillo G, Tedeschi A, et al. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. Haematologia 89: 361-363, 2004.